释放NO的热石及其抗血栓性质
Paul S Wheatley1, Anthony R Butler, Michael S Crane
1School of Chemistry, University of St. Andrews, Purdie Building, UK.
Journal of the American Chemical Society
|January 13, 2006
概括
过渡金属交换的化物-A有效地储存氧化 (NO) 并将其释放到水中. 这种NO释放抑制了血小板聚合,显示了医学应用的潜力.
科学领域:
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
- 化学 化学 化学
背景情况:
- 泽奥利特-A可以吸附和储存分子.
- 氧化 (NO) 具有生物信号功能.
- 对于治疗应用而言,控制NO的释放是可取的.
研究的目的:
- 为了研究过渡金属交换的化物-A对氧化物 (NO) 吸附和储存的能力.
- 探索存储的NO的控制释放的条件和方法.
- 评估释放的NO的生物活性,特别是它对人类血小板的作用.
主要方法:
- 合成和表征过渡金属交换的焦化-A.A.
- 在受控条件下吸附和储存NO.
- 在实验室中研究由水性环境触发的NO释放.
- 对NO对血小板聚合和粘附的影响的评估.
主要成果:
- 泽奥利特-A显示出高NO吸附能力 (高达1mmolNO/g).
- 在接触生物相关温度和pH值的水溶液时观察到NO的释放.
- 释放动力学可以通过修改热带石组成,水接触和聚合物混合来调整.
- 同时交换的酸-A释放的NO抑制了人体血小板聚合和粘附 in vitro.
结论:
- 过渡金属交换的焦化-A是高容量NO存储的有希望的材料.
- 控制释放的氧化从热-A可以调节为特定的应用.
- 观察到的释放的NO的抗血小板活性表明,在血栓形成和血液静止中具有潜在的治疗用途.
相关概念视频
Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...


